US · VSTM · BIOTECHNOLOGY
Verastem, Inc. (VSTM) intrinsic value and stock valuation
$6.33as of 2026-11-21 · Mkt cap 515.82M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Verastem, Inc. DCF and intrinsic value
InvestorsCraft values VSTM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VSTM’s statements →
Verastem, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $30.9M | $10M | $0.00 | $2.6M | $2.05M |
| Operating income | -$-170.13M | -$-114.96M | -$-92.08M | -$-72.94M | -$-61.41M |
| Net income | -$-209.47M | -$-130.64M | -$-87.37M | -$-73.81M | -$-71.2M |
| EPSd | -$-3.02M | -$-3.66M | -$-3.96M | -$-4.57M | -$-4.9M |
| Operating cash flow | -$-137.51M | -$-104.77M | -$-86.46M | -$-63.67M | -$-53.5M |
| Capital expenditure | $0.00 | -$-30K | $0.00 | $0.00 | -$-200K |
| Free cash flow | -$-137.51M | -$-104.8M | -$-86.46M | -$-63.67M | -$-53.7M |
| Total assets | $246.4M | $101.5M | $149.7M | $95.1M | $108.7M |
| Total debt | $76.9M | $42.3M | $41.6M | $27.1M | $3.18M |
| Net debt | -$-128.12M | -$-46.56M | -$-36.35M | -$-47.87M | -$-18.07M |
| Total equity | $57.2M | -$-28.89M | $57.4M | $47.4M | $87.6M |
| Cash and short-term investments | $205M | $88.8M | $137.1M | $87.9M | $100.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $30.9M | $10M | $0.00 | $2.6M | $2.05M |
| Cost of revenue | $5.3M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $25.6M | $10M | $0.00 | $2.6M | $2.05M |
| Research and development expenses | $114.6M | $81.3M | $61.4M | $50.6M | $39.4M |
| Selling, general and administrative expenses | $81.2M | $43.6M | $30.7M | $25M | $24.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $195.8M | $125M | $92.1M | $75.5M | $63.5M |
| Cost and expenses | $201M | $125M | $92.1M | $75.5M | $63.5M |
| Interest income | $4.07M | $4.15M | $6.21M | $1.22M | $180K |
| Interest expense | $1.14M | $4.56M | $4.14M | $2.14M | $9.97M |
| Depreciation and amortization | $730K | $30K | $60K | $120K | $70K |
| Ebitda | -$-207.6M | -$-125.86M | -$-83.17M | -$-71.56M | -$-61.16M |
| Operating income | -$-170.13M | -$-114.96M | -$-92.08M | -$-72.94M | -$-61.41M |
| Total other income/expenses, net | -$-39.34M | -$-15.5M | $4.72M | -$-880K | -$-9.79M |
| Income before tax | -$-209.47M | -$-130.45M | -$-87.37M | -$-73.81M | -$-71.2M |
| Income tax expense | $0.00 | $180K | $0.00 | $0.00 | $0.00 |
| Net income | -$-209.47M | -$-130.64M | -$-87.37M | -$-73.81M | -$-71.2M |
| Weighted average shares outstanding | $69.3M | $35.7M | $22.1M | $16.1M | $14.5M |
| Weighted average diluted shares outstanding | $69.3M | $35.7M | $22.1M | $16.1M | $14.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $205M | $88.8M | $137.1M | $87.9M | $100.3M |
| Net receivables | $8.81M | $200K | $0.00 | $30K | $520K |
| Inventory | $1.83M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $223.4M | $95M | $143.7M | $92.9M | $105.7M |
| Property, plant and equipment, net | $490K | $1.44M | $1.21M | $1.88M | $2.51M |
| Goodwill and intangible assets | $16.4M | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $240K | $0.00 |
| Total non-current assets | $23M | $6.58M | $6.04M | $2.18M | $2.92M |
| Total assets | $246.4M | $101.5M | $149.7M | $95.1M | $108.7M |
| Accounts payable | $12.5M | $4.03M | $7.18M | $4.9M | $2.3M |
| Short-term debt | $540K | $990K | $940K | $1.07M | $670K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $710K | $0.00 |
| Total current liabilities | $72.3M | $31M | $26.4M | $21.7M | $18.6M |
| Long-term debt | $76.3M | $41.3M | $40.6M | $26M | $2.51M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $117M | $99.5M | $66M | $26M | $2.51M |
| Capital lease obligations | $0.00 | $1.53M | $1.47M | $2.26M | $2.93M |
| Total liabilities | $189.3M | $130.4M | $92.3M | $47.7M | $21.1M |
| Common stock | $10K | $0.00 | $0.00 | $20K | $20K |
| Retained earnings | -$-1.17B | -$-955.53M | -$-824.89M | -$-737.52M | -$-663.71M |
| Accumulated other comprehensive income (loss) | $5.23M | $0.00 | $10K | $0.00 | $30K |
| Total equity | $57.2M | -$-28.89M | $57.4M | $47.4M | $87.6M |
| Total investments | $0.00 | $0.00 | $59.2M | $13.2M | $79M |
| Total debt | $76.9M | $42.3M | $41.6M | $27.1M | $3.18M |
| Net debt | -$-128.12M | -$-46.56M | -$-36.35M | -$-47.87M | -$-18.07M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-209.47M | -$-130.64M | -$-87.37M | -$-73.81M | -$-71.2M |
| Depreciation and amortization | $730K | $30K | $60K | -$-40K | $70K |
| Stock-based compensation | $9.4M | $7.34M | $5.86M | $6.05M | $7.71M |
| Change in working capital | $26M | $3.72M | -$-960K | $3.9M | $580K |
| Accounts receivable | -$-8.81M | -$-200K | $30K | $480K | -$-280K |
| Inventory | -$-1.83M | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $8.42M | -$-3.16M | $2.28M | $2.6M | $620K |
| Net cash provided by operating activities | -$-137.51M | -$-104.77M | -$-86.46M | -$-63.67M | -$-53.5M |
| Investments in property, plant and equipment | -$-9.62M | -$-30K | $0.00 | $0.00 | -$-200K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $9.33M |
| Net cash used for investing activities | -$-9.62M | $60M | -$-44.45M | $66.2M | $90K |
| Common stock issued | $230.9M | $14.2M | $91.4M | $27.4M | $6.72M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $263.3M | $54.8M | $134.2M | $51.8M | $6.88M |
| Net change in cash | $116.2M | $9.98M | $3.29M | $54.3M | -$-46.53M |
| Cash at end of period | $205.2M | $89.1M | $79.1M | $75.8M | $21.5M |
| Operating cash flow | -$-137.51M | -$-104.77M | -$-86.46M | -$-63.67M | -$-53.5M |
| Capital expenditure | $0.00 | -$-30K | $0.00 | $0.00 | -$-200K |
| Free cash flow | -$-137.51M | -$-104.8M | -$-86.46M | -$-63.67M | -$-53.7M |
Line items
Line items
Line items
About Verastem, Inc.
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.
- CEO
- Daniel W. Paterson
- Employees
- 102
- Beta
- 0.29
Explore
Frequently asked questions
What is the intrinsic value of Verastem, Inc. (VSTM)?
Verastem, Inc. (VSTM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is VSTM undervalued?
VSTM trades at a price of $6.33 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.